Navigation Links
Lexicon Pharmaceuticals Announces Reacquisition of All Rights to Symphony Icon Programs
Date:8/2/2010

% of any payment made on or prior to July 30, 2012 will be paid in common stock and no more than 50% of any payment made after such date will be paid in common stock.

LX1031 is an orally-delivered serotonin synthesis inhibitor that acts locally in the gastrointestinal tract targeting tryptophan hydroxylase (TPH), an enzyme necessary for the production of serotonin.  LX1031 recently demonstrated positive results in a Phase 2 clinical trial in patients with diarrhea-predominant and mixed forms of irritable bowel syndrome (IBS-D and IBS-M).  LX1032 is an orally-delivered serotonin synthesis inhibitor that acts peripherally to inhibit tryptophan hydroxylase without affecting brain serotonin levels.  LX1032 is currently in a Phase 2 clinical trial in patients with carcinoid syndrome.  LX1033 is a locally acting serotonin synthesis inhibitor with enhanced potency in IND-enabling studies.

Lexicon Conference Call:

Lexicon management will hold a conference call to discuss its reacquisition of the Symphony Icon programs at 3:00 p.m. Eastern Time on August 2, 2010.  The dial-in number for the conference call is 888-220-1244 (within the US/Canada) or 706-679-5615 (international).  The conference ID for all callers is 91995968.  An archived version of the conference call will be available on the Lexicon website through August 9, 2010.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease.  Lexicon currently has four drug candidates in mid-stage development for diabetes, irritable bowel syndrome, carcinoid syndrome and rheumatoid ar
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Lexicon Presents Data Describing LX4211 Positive Phase 2 Clinical Results and Novel Mechanism of Action for Type 2 Diabetes
2. Lexicon Presents Positive Outcome in IBS Patients Treated With LX1031 and Data Supporting Mechanism of Action
3. Lexicon to Provide Clinical Pipeline Update and Report First Quarter 2010 Financial Results
4. Lexicon to Present at BIO International Convention
5. Lexicon to Present Phase 2 Clinical Data for IBS Drug Candidate at Digestive Disease Week
6. Lexicon Announces Proposed $95 Million Common Stock Offering
7. Lexicon to Report Fourth Quarter and Year End 2009 Financial Results on February 23, 2010
8. Lexicon Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
9. Lexicon to Host Conference Call and Webcast to Review Top-Line Phase 2 Results From Diabetes Trial
10. Lexicon to Present Positive Top-Line Phase 2 Results for LX1031 in Non-Constipating Irritable Bowel Syndrome at GASTRO 2009
11. Lexicon Announces Positive Phase 2 Results of LX1031 in Non-Constipating Irritable Bowel Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 19, 2014  BioSpecifics Technologies Corp. (NASDAQ: BSTC ... marketed as XIAFLEX ® in the U.S. and XIAPEX ... Tom Wegman , will present a corporate overview at ... Industry Conference. The presentation will take place ... the Millennium Broadway Hotel in New York, NY ...
(Date:9/19/2014)... Tenn. , Sept. 19, 2014  Over 200 ... the Future to Benefit the Radiation Oncology Institute (ROI), ... held at Golden Gate Park in San Francisco.  ... Dan Moore , CEO of Radiation Business Solutions, ... we have raised over $70,000 for the ROI this ...
(Date:9/19/2014)... CAMBRIDGE, Mass. , Sept. 19, 2014 ... a provider of advanced cancer genome analysis and ... leader in discovering and developing highly selective kinase ... first-ever comprehensive genomic study of malignant mixed Mullerian ... the female reproductive system, also known as carcinosarcoma. ...
Breaking Medicine Technology:BioSpecifics Technologies Corp. to Present at the 21st Annual BioCentury NewsMakers in the Biotech Industry Conference 2Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 2Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 3First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 2First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 3First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 4
... 17, 2007 /PRNewswire-FirstCall/ --,Telik, Inc. announced the ... clinical trial of the triplet combination of ... the,first-line treatment of advanced non-small cell lung ... significant,improvement in both progression-free survival and overall ...
... Antiproliferative and Antiangiogenic Activity Demonstrated in,Preclinical ... Md., April 17, 2007 /PRNewswire-FirstCall/ --,EntreMed, ... developing,therapeutics for the treatment of cancer ... of preclinical data for its,clinical-stage product ...
Cached Medicine Technology:Telik Reports Positive Data Demonstrating Synergy in Combination,and Highly Statistically Significant Effect of Telcyta as,Maintenance Therapy in First-Line Non-Small Cell Lung Cancer 2Telik Reports Positive Data Demonstrating Synergy in Combination,and Highly Statistically Significant Effect of Telcyta as,Maintenance Therapy in First-Line Non-Small Cell Lung Cancer 3Telik Reports Positive Data Demonstrating Synergy in Combination,and Highly Statistically Significant Effect of Telcyta as,Maintenance Therapy in First-Line Non-Small Cell Lung Cancer 4EntreMed Presents Multi-Mechanism Results for ENMD-1198 at AACR,Annual Meeting 2EntreMed Presents Multi-Mechanism Results for ENMD-1198 at AACR,Annual Meeting 3EntreMed Presents Multi-Mechanism Results for ENMD-1198 at AACR,Annual Meeting 4
(Date:9/20/2014)... 20, 2014 Plumbing construction services ... of 5, indicating a moderately favorable purchasing environment for ... reflects current and future pricing trends that will limit ... Other factors that negatively affect buyer power are a ... and the moderate switching costs. Buyers benefit, however, from ...
(Date:9/20/2014)... Final Cut Pro X Plugin developers ... Information theme for FCPX filmmakers. , “Fun, cool, and simple ... theme,” says Christina Austin, CEO of Pixel Film Studios. “It ... Information features easy to use controls that give the user ... the background color, color of each circle outline, the position ...
(Date:9/20/2014)... September 20, 2014 MarijuanaDoctors.com recently ... showing at the PAIN Week conference that was ... and Casino in Las Vegas from September 2nd ... attended PAIN Week in the hopes of educating ... viable and legitimate tool to treat chronic Pain, ...
(Date:9/19/2014)... DC) (PRWEB) September 19, 2014 “Copay ... inflate sales of brand drugs among patients with prescription ... according to a new report from the ... Inspector General (OIG). Federal anti-kickback laws prohibit suppliers from ... subsidized by the federal government. , The report highlights ...
(Date:9/19/2014)... FRIDAY, Sept. 19, 2014 (HealthDay News) -- As kids ... the targets of cyberbullies, according to a recent study. ... grades 5 through 8 found that verbal and physical ... patterns vary, bullying intervention and prevention strategies must address ... bullying among boys and girls, the researchers said. The ...
Breaking Medicine News(10 mins):Health News:Plumbing Construction Services Procurement Category Market Research Report from IBISWorld Has Been Updated 2Health News:Plumbing Construction Services Procurement Category Market Research Report from IBISWorld Has Been Updated 3Health News:Plumbing Construction Services Procurement Category Market Research Report from IBISWorld Has Been Updated 4Health News:Today Pixel Film Studios Announced the Release of the Information Theme for Final Cut Pro X 2Health News:MarijuanaDoctors.com Experiences Unprecedented Support and Growth at Pain Week 2014 2Health News:PCMA: New OIG Report Cites Drug Manufacturer“Copay Coupon” Use in Medicare Part D 2Health News: Cyberbullying Seems to Ramp Up in Middle School 2
... , , , FOSTER ... WHAT: Siperian, Inc., a leading industry provider of a multidomain master ... IBM Global Business Services and Boehringer Ingelheim have teamed up for an ... Most Valuable?" Hussain Mooraj, vice president, Healthcare ...
... HONG KONG, Sept. 16 /PRNewswire-Asia/ -- At ... September 10, reporters were informed that the,First World Conference ... Physicians) and the First World Endoscopy Technology Expo,will be ... Professor Zhang Yangde, the chief ...
... HBV genotypes as well as mutations in the core promoter, ... association with the clinical outcome of liver disease, however, this ... the HBV genotype distribution in certain region. So far, there ... country with a big population and a relatively high HBV ...
... , , MENLO PARK, ... label-free technology that accelerates the development of biotherapeutic and pharmaceutical ... and Read Immunogenicity Assay Kit for rapid detection of anti-drug ... new assay kit provides life science researchers with new levels ...
... , , , NEW YORK, ... has received Orphan-Drug designation from the U.S. Food and Drug Administration ... announced that it had reached an agreement with the FDA regarding ... 3 trial in relapsed/refractory multiple myeloma and that the study is ...
... study finds supervised exercise has better results , WEDNESDAY, ... than shockwave treatment for relieving chronic shoulder pain, according ... used to treat shoulder pain, even though a number ... investigate, Norwegian researchers studied 104 men and women, aged ...
Cached Medicine News:Health News:Siperian to Host Webinar With Panel of Pharmaceutical Experts 2Health News:Siperian to Host Webinar With Panel of Pharmaceutical Experts 3Health News:Siperian to Host Webinar With Panel of Pharmaceutical Experts 4Health News:Siperian to Host Webinar With Panel of Pharmaceutical Experts 5Health News:The First World Conference of Endoscopy Physicians will be Held December 18-20, 2009, in Hong Kong 2Health News:The First World Conference of Endoscopy Physicians will be Held December 18-20, 2009, in Hong Kong 3Health News:ForteBio Launches Dip and Read(TM) Immunogenicity Assay Kit for Rapid Detection of Anti-Drug Antibodies 2Health News:Keryx Biopharmaceuticals Receives Orphan-Drug Designation for KRX-0401 (Perifosine) for the Treatment of Multiple Myeloma 2Health News:Keryx Biopharmaceuticals Receives Orphan-Drug Designation for KRX-0401 (Perifosine) for the Treatment of Multiple Myeloma 3Health News:Keryx Biopharmaceuticals Receives Orphan-Drug Designation for KRX-0401 (Perifosine) for the Treatment of Multiple Myeloma 4Health News:Shockwave Treatment May Not Be Best for Shoulder Pain 2
The NPT7 blood gas analyzer measures pH/blood gases and oximetry on 90 L sample volume with a two-step sampling procedure. Clinical tests compare NPT7 accuracy to that of benchtop analyzers. 30 sampl...
... is a fully automated, upgradeable platform ... gas analyzer along with a customer ... freedom to focus on patient care. ... that are essential to efficient blood ...
... Helmer Platelet Agitators feature ... with non-slip texture coating ... circulation for your platelets. ... to be used in ...
... agitators offer a wide range of storage ... drawer storage platform to agitate smoothly, eliminating ... down and squeak. Sturdy, one-piece perforated drawers ... circulation for your platelets., ,i.Series platelet agitators ...
Medicine Products: